Navigation Links
PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
Date:8/20/2007

Analysis published in the journal Blood found 92 percent reduction in

incidence of thromboses

CHESHIRE, Conn., Aug. 20 /PRNewswire-FirstCall/ -- Patients with a rare blood disorder called PNH experienced a 92 percent reduction in the incidence of life-threatening blood clots (thromboses) following treatment with Soliris(TM) (eculizumab), according to an analysis of clinical studies recently published online in Blood, the journal of the American Society of Hematology.

Soliris, developed by Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN), is the first therapy approved for paroxysmal nocturnal hemoglobinuria (PNH), a rare, debilitating and life-threatening blood disorder defined by the destruction of red blood cells, or hemolysis. In patients with PNH, hemolysis can cause severe anemia, disabling fatigue, recurrent pain, shortness of breath, pulmonary hypertension, intermittent episodes of dark colored urine (hemoglobinuria), kidney disease, impaired quality of life and thromboses. (1,2)

"Thrombosis is the leading cause of premature death in PNH patients and the most feared complication of PNH," said Dr. Peter Hillmen, senior author of the paper and Consultant Haematologist of the General Infirmary at Leeds, Leeds, UK. "In several clinical trials, Soliris reduced hemolysis in all PNH patients and significantly improved anemia, fatigue and quality of life. The comprehensive analyses demonstrate that Soliris substantially reduced the risk of thrombosis in a diverse population of PNH patients, including those who might be expected to have less severe disease."

Approximately 40 percent of patients with PNH experience thrombosis during the course of the disease.(3,4,5,6) An ini
'/>"/>

SOURCE Alexion Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Hematology Analyzers Simple, Sophisticated Technology Serving All Patients
2. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
3. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
4. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
5. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
6. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
7. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
8. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
9. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
10. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
11. Skin Rash Actually Signifies Better Outcomes for Pancreatic and Lung Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... July 29, 2015  Cepheid (Nasdaq: CPHD ... update to Xpert® Carba-R, with the addition of ... The on-demand, molecular test also detects and differentiates ... resistance, namely KPC, NDM, VIM, IMP-1 and OXA-48. ... CROs or Superbugs, are a growing and expensive ...
(Date:7/29/2015)... MOUNTAIN VIEW, Calif. , July 29, 2015 /PRNewswire/ ... in the growth strategy of pharmaceutical firms in ... . The realization is that an effective working ... sales, pricing pressures and patent cliffs. Big pharma companies ... bolster returns. Logo - http://photos.prnewswire.com/prnh/20150724/241957LOGO ...
(Date:7/29/2015)... , July 29, 2015 ... Therapeutic Vaccines Market - Growth, Trends & Forecasts (2015-2020) ... expected to be worth US$ 2.85 billion by the ... being the largest market globally accounting for more ... market for Therapeutic Vaccines is expected to grow at ...
Breaking Medicine Technology:'Superbug' Test Updated to Identify Newest Carbapenem-Resistant Organisms 2'Superbug' Test Updated to Identify Newest Carbapenem-Resistant Organisms 3'Superbug' Test Updated to Identify Newest Carbapenem-Resistant Organisms 4Working Capital Management Seizes Priority in North American and European Pharma Industry 2Working Capital Management Seizes Priority in North American and European Pharma Industry 3Working Capital Management Seizes Priority in North American and European Pharma Industry 4New Approaches and Technical Advances by Major Players Like Novartis, Merck KGaA, Pfizer, GlaxoSmithKline and Others to Elevate the Global Therapeutic Vaccines Market 2New Approaches and Technical Advances by Major Players Like Novartis, Merck KGaA, Pfizer, GlaxoSmithKline and Others to Elevate the Global Therapeutic Vaccines Market 3
... Surgical, recently named one of Philadelphia,s 100 Fastest ... the healthcare marketplace with the acquisition of the ... surgical facilities to Millennium Surgical,s resources.  Its acquisition ... company has been undertaking for several years.  Millennium ...
... March 23, 2011 Polar ( ... assessment technology, today announced a partnership with celebrity fitness trainer ... president and CEO of NGR™ / No Gym Required™ ... a new show on the CW network, as a spokesperson ...
Cached Medicine Technology:Millennium Surgical adds "SurgicalInstruments.com" Name 2Polar Partners with 'Shedding for the Wedding' Trainer and NGR™ President and CEO Jennifer Cohen 2Polar Partners with 'Shedding for the Wedding' Trainer and NGR™ President and CEO Jennifer Cohen 3
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... ... a decision from the Judicial Panel on Multidistrict Litigation (JPML), according to court ... defects research at their website, the Zofran Birth Defects Lawsuit Center. , GlaxoSmithKline, ...
(Date:7/29/2015)... ... July 29, 2015 , ... " mybody ” was featured ... small, medium and large businesses making an impact in their industry. Andrew Tropeano, the ... how these advanced probiotic skincare products are designed to strengthen the skin’s defense system ...
(Date:7/29/2015)... , ... July 29, 2015 , ... ... it has entered into a partnership with 247Ergo, an ergonomics specialty firm. Purpose ... wellness. Ergonomics projects that the companies undertake could improve worker mobility, functionality and ...
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... ... illnesses is seeking funding for a study on the potentially lifesaving impact of ... Institute today . , The research proposal is based on a successful ...
(Date:7/29/2015)... Rosa, CA (PRWEB) , ... July 29, 2015 , ... ... hernias have advanced as a result. Information provided by the National Center for ... – and three million new cases are reported annually. While the only effective ...
Breaking Medicine News(10 mins):Health News:Zofran Lawsuit News: Zofran Lawsuits Stayed, Awaiting MDL Decision 2Health News:Zofran Lawsuit News: Zofran Lawsuits Stayed, Awaiting MDL Decision 3Health News:Zofran Lawsuit News: Zofran Lawsuits Stayed, Awaiting MDL Decision 4Health News:Strengthen the Skin’s Defense System from the Inside Out with mybody 2Health News:HealthPostures and 247Ergo Partnership Strengthens America's Wellness 2Health News:HealthPostures and 247Ergo Partnership Strengthens America's Wellness 3Health News:Children's Medical Safety Research Institute Announces Innovative Study on Alzheimer’s Treatment Is Subject of Crowd Funding Campaign 2Health News:Children's Medical Safety Research Institute Announces Innovative Study on Alzheimer’s Treatment Is Subject of Crowd Funding Campaign 3Health News:National Statistics Reflect NCMA General Surgery Physicians Findings: Hernia Patients Who Seek Treatment Promptly are More Likely to Enjoy a Quick Recovery 2Health News:National Statistics Reflect NCMA General Surgery Physicians Findings: Hernia Patients Who Seek Treatment Promptly are More Likely to Enjoy a Quick Recovery 3
... chronic myeloid leukemia patients who are out of treatment options ... their cancer cells have a mutation that makes them resistant ... of the American Society of Hematology. In a Phase ... hematologic responses (absence of CML cells in the blood) and ...
... inhibitors are substantially improving treatment of myelofibrosis ( ... http://www.mayoclinic.org/ ) researchers who are presenting results of ... of the American Society of Hematology ( http://www.hematology.org/ ... VIDEO ALERT: Additional audio and video resources, including ...
... Texas AgriLife Research engineers has developed a way to cut ... to kill 99.999 percent of salmonella, E. coli ... in a Mylar bag filled with pure oxygen, Dr. Carmen ... they could significantly reduce the amount of radiation needed to ...
... HealthDay Reporter , SUNDAY, Dec. 5 (HealthDay ... they managed to "correct" a malfunctioning gene responsible for ... leads to prolonged bleeding from even minor hits or ... cancers and dangerous infections. However, one of the ...
... Reporter , SATURDAY, Dec. 4 (HealthDay News) -- A new ... safer treatment for patients coping with deep-vein thrombosis (DVT), a ... published online Dec. 4 in the New England Journal ... for these potentially life-threatening clots, which most typically form ...
... Quigley will describe a promising new approach to blocking ... meeting in Orlando, Fla. Quigley will speak at ... at the Orange County Convention Center, 9800 International Drive, ... the Human Erythroid Heme Exporter, FLVCR, Export Heme: Potential ...
Cached Medicine News:Health News:Phase I trial indicates ponatinib may thwart most resistant CML 2Health News:JAK inhibitors producing significant response in myelofibrosis patients 2Health News:JAK inhibitors producing significant response in myelofibrosis patients 3Health News:AgriLife researchers find way to cut food-irradiation levels by half 2Health News:AgriLife researchers find way to cut food-irradiation levels by half 3Health News:AgriLife researchers find way to cut food-irradiation levels by half 4Health News:Gene Therapy Corrected Rare Bleeding Disorder: Study 2Health News:Gene Therapy Corrected Rare Bleeding Disorder: Study 3Health News:New Blood Thinner May Help Fight Dangerous Leg Clots 2Health News:New Blood Thinner May Help Fight Dangerous Leg Clots 3Health News:UIC researcher unveils new approach to blocking malaria transmission 2
Designed to minimize emblolic debris in SVGs and carotids...
... The dual lumen titanium ... 1.2 mm inner diameter ... oval lumen catheters offer ... maintaining maximum catheter strength. ...
The standard-sized titanium port may be ordered with a silicone or polyurethane catheter. The silicone catheter is available with inner diameter sizes of 0.9, 1.0, 1.4, 1.6 mm. The polyurethane cathe...
... The Statscan Critical Imaging System is ... aimed specifically at the needs of emergency ... the radiography needs of both trauma patients ... life-saving information to the medical staff by ...
Medicine Products: